- Home
- CHRS vs PCF Comparison
CHRS vs PCF Comparison
Compare CHRS & PCF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- PCF
- Stock Information
- Founded
- CHRS 2010
- PCF 1987
- Country
- CHRS United States
- PCF United States
- Employees
- CHRS 177
- PCF N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- PCF Trusts Except Educational Religious and Charitable
- Sector
- CHRS Health Care
- PCF Finance
- Exchange
- CHRS Nasdaq
- PCF Nasdaq
- Market Cap
- CHRS 149.9M
- PCF 119.3M
- IPO Year
- CHRS 2014
- PCF N/A
- Fundamental
- Price
- CHRS $1.37
- PCF $6.42
- Analyst Decision
- CHRS Strong Buy
- PCF
- Analyst Count
- CHRS 4
- PCF 0
- Target Price
- CHRS $4.51
- PCF N/A
- AVG Volume (30 Days)
- CHRS 1.4M
- PCF 74.8K
- Earning Date
- CHRS 11-05-2025
- PCF 01-01-0001
- Dividend Yield
- CHRS N/A
- PCF 10.90%
- EPS Growth
- CHRS N/A
- PCF N/A
- EPS
- CHRS 1.55
- PCF N/A
- Revenue
- CHRS $272,209,000.00
- PCF N/A
- Revenue This Year
- CHRS N/A
- PCF N/A
- Revenue Next Year
- CHRS $126.00
- PCF N/A
- P/E Ratio
- CHRS $0.88
- PCF N/A
- Revenue Growth
- CHRS 52.33
- PCF N/A
- 52 Week Low
- CHRS $0.66
- PCF $5.71
- 52 Week High
- CHRS $2.43
- PCF $6.96
- Technical
- Relative Strength Index (RSI)
- CHRS 73.83
- PCF 50.59
- Support Level
- CHRS $1.26
- PCF $6.34
- Resistance Level
- CHRS $1.39
- PCF $6.51
- Average True Range (ATR)
- CHRS 0.08
- PCF 0.05
- MACD
- CHRS 0.02
- PCF -0.00
- Stochastic Oscillator
- CHRS 94.10
- PCF 47.06
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About PCF High Income Securities Fund
High Income Securities Fund is a closed-end management investment company. Its primary objective is to provide high current income and capital appreciation is the secondary objective. The Fund pursues its objective primarily by investing in both convertible bonds and convertible preferred stocks. The Fund also invests significantly in high-yielding non-convertible securities with the potential for capital appreciation.